• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis . High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease

tetano

Editor, Senior Moderator
Clin Infect Dis


. 2020 Sep 23;ciaa1054.
doi: 10.1093/cid/ciaa1054. Online ahead of print.
High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease


Catherine A Hogan[SUP] 1 2 [/SUP], Bryan A Stevens[SUP] 1 2 [/SUP], Malaya K Sahoo[SUP] 1 [/SUP], ChunHong Huang[SUP] 1 [/SUP], Natasha Garamani[SUP] 1 [/SUP], Saurabh Gombar[SUP] 1 [/SUP], Fumiko Yamamoto[SUP] 1 [/SUP], Kanagavel Murugesan[SUP] 1 [/SUP], Jason Kurzer[SUP] 1 [/SUP], James Zehnder[SUP] 1 [/SUP], Benjamin A Pinsky[SUP] 1 2 3 [/SUP]



Affiliations

Abstract

Background: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in blood, also known as RNAemia, has been reported, but its prognostic implications are poorly understood. This study aimed to determine the frequency of SARS-CoV-2 RNA in plasma and its association with coronavirus disease 2019 (COVID-19) clinical severity.
Methods: An analytical cross-sectional study was performed in a single-center tertiary care institution and included consecutive inpatients and outpatients with confirmed COVID-19. The prevalence of SARS CoV-2 RNAemia and the strength of its association with clinical severity variables were examined and included intensive care unit (ICU) admission, invasive mechanical ventilation, and 30-day all-cause mortality.
Results: Paired nasopharyngeal and plasma samples were included from 85 patients. The median age was 55 years, and individuals with RNAemia were older than those with undetectable SARS-CoV-2 RNA in plasma (63 vs 50 years; P = .04). Comorbidities were frequent including obesity (37.6%), hypertension (30.6%), and diabetes mellitus (22.4%). RNAemia was detected in 28/85 (32.9%) of patients, including 22/28 (78.6%) who required hospitalization. In models adjusted for age, RNAemia was detected more frequently in individuals who developed severe disease including ICU admission (32.1 vs 14.0%; P = .04) and invasive mechanical ventilation (21.4% vs 3.5%; P = .02). All 4 deaths occurred in individuals with detectable RNAemia. An additional 121 plasma samples from 28 individuals with RNAemia were assessed longitudinally, and RNA was detected for a maximum duration of 10 days.
Conclusions: This study demonstrated a high proportion of SARS-CoV-2 RNAemia, and an association between RNAemia and clinical severity suggesting the potential utility of plasma viral testing as a prognostic indicator for COVID-19.

Keywords: COVID-19; RNAemia; SARS-CoV-2; blood; severity.
 
Back
Top Bottom